The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million in a second-round financing that will support the launch of a tool that can ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Daiichi Sankyo has reported its delayed financial results, saying that high spending on third-party manufacturing and a lower-than-expected take-up of its antibody-drug conjugates for cancer led to a ...

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological diseases – a mission that will be helped by adding ...

Longevity investment went from $3.8bn in 2023 to $8.5bn in 2024 (albeit in the context of a broader biotech market recovery).

Danish GLP-1 giant Novo Nordisk announced a restructuring effort today that will cut 9,000 jobs, a little over 11% of its global workforce. The cut comes a little over a month after the start of new ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...

Eisai has won a patent infringement lawsuit brought against Shilpa Medicare that sought to prevent the Indian generic drugmaker from launching a version of its MSD-partnered cancer drug Lenvima in the ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...

A year ago, Iovance was celebrating becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour. Now, it is cutting staff in the face of sales growth that has not ...